©2024 Stanford Medicine
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Not Recruiting
Trial ID: NCT04833959
Purpose
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular
imaging agent in patients with (metastatic) pancreas cancer.
Official Title
Pilot Study of 89Zr Panitumumab in Pancreas Cancer
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
George A. Poultsides, MD, MS
Professor of Surgery (General Surgery) at the Stanford University Medical Center
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
Inclusion Criteria:
- Confirmed diagnosis of pancreatic cancer.
Exclusion Criteria:
- Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
heart failure (CHF); significant liver disease; or unstable angina within 6 months
prior to enrollment.
- History of infusion reactions to monoclonal antibody therapies.
- Pregnant or breastfeeding.
- Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide,
amiodarone, sotalol) antiarrhythmic agents.
- Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
- Severe renal disease or anuria.
- Known hypersensitivity to deferoxamine or any of its components.
Intervention(s):
drug: 89Zr-panitumumab
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Alexander A Valencia
650-498-5185